The World Intellectual Property Organization has published Quantumzyme Corp.'s international patent application for modified polypeptides used in enzymatic synthesis of ibuprofen, marking a substantial advancement in sustainable pharmaceutical manufacturing. The patent publication (WO 2025/093935 A1) complements the company's previously announced U.S. Patent Application (US 2025/0146029 A1), creating comprehensive intellectual property protection for Quantumzyme's enzyme engineering platform across both domestic and international markets.
This development represents a critical milestone in transforming how common pharmaceuticals like ibuprofen are manufactured. The patented biocatalytic method replaces traditional chemical synthesis with enzyme-mediated processes that significantly reduce chemical waste, eliminate harsh reagents, and improve overall manufacturing efficiency. This approach addresses growing environmental concerns within the pharmaceutical industry while potentially lowering production costs and improving sustainability metrics.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated that the patent publications validate the company's enzyme engineering technology and strengthen its position for global partnerships focused on greener pharmaceutical manufacturing. The technology enables Quantumzyme to advance into optimization and pilot-testing phases while engaging with potential partners interested in sustainable active pharmaceutical ingredient production.
The enzymatic ibuprofen synthesis builds upon Quantumzyme's proprietary QZyme Workbench platform, which integrates quantum mechanics, molecular modeling, and artificial intelligence-driven optimization to design advanced biocatalysts. This underlying technology supports multiple enzyme systems the company is developing for sustainable production of active pharmaceutical ingredients and specialty chemicals.
Looking forward, Quantumzyme plans to continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process while pursuing discussions with global pharmaceutical companies and contract manufacturing organizations regarding licensing or joint-development arrangements. The company also intends to file additional patent applications covering related enzymatic transformations and process improvements. For additional information, visit https://www.quantumzymecorp.com and https://www.otcmarkets.com/stock/QTZM.
The significance of this development extends beyond intellectual property protection to potentially transform pharmaceutical manufacturing practices worldwide. As regulatory pressure increases for greener manufacturing processes and consumers demand more environmentally responsible products, enzymatic synthesis methods could become standard across the industry. This technology demonstrates how biotechnology can enable more sustainable production of essential medications while maintaining efficiency and scalability required for global supply chains.
